Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immunology and inflammation, announced the pricing of its upsized initial public offering (IPO) of common stock.

Bambusa Therapeutics has reported the pricing of 10,555,555 shares of common stock at a public offering price of $16.00 per share. The gross proceeds are expected to reach approximately $168,888,880 before deductions for underwriting discounts, commissions, and other offering expenses. Additionally, the company has granted underwriters a 30-day option to purchase up to an additional 1,583,333 shares at the initial public offering price.

Trading Schedule and Financial Details

• Ticker Symbol: BBTX
• Exchange: Nasdaq Global Select Market
• Expected Trading Start: October 30, 2026
• Expected Closing Date: November 2, 2026, subject to customary closing conditions
• Joint Book-Running Managers: BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor

The registration statements for these securities were filed with the U.S. Securities and Exchange Commission (SEC) and became effective on October 29, 2026.

Company Pipeline and Focus

Bambusa Therapeutics develops long-acting precision bispecific antibodies targeted at immunology and inflammation. Its pipeline features:

• BBT001: Targeting IL-4Rα and IL-31 for atopic dermatitis and inflammatory skin conditions.
• BBT002: Targeting IL-4Rα and IL-5 for Type 2 inflammatory disorders.
• Preclinical Programs: BBT003 (gastroenterology) and BBT004 (autoantibody-driven autoimmune diseases).

Practical Implications and Verification

Investors and interested parties can verify official filings and obtain prospectus copies through the SEC website at www.sec.gov or by contacting the managing financial institutions directly. Prospective participants should note that forward-looking statements regarding trading dates and offering completion are subject to market risks and customary closing conditions.